Q-omics provides the consensus-scored REM2 profile across patient tissues and cancer cell-line models. REM2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, REM2 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, REM2 RNA expression shows 17,579 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, KICH, and ACC as cancer lineages where REM2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for REM2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes REM2 survival associations across molecular data types. REM2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible REM2 RNA expression–survival associations across cancer types. High REM2 expression shows unfavorable associations in KIRC, ACC and KICH, but favorable associations in BRCA, PAAD and OV. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for REM2 RNA expression.
This table summarizes REM2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for REM2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. REM2 shows lower tumor expression in KICH and KIRC and higher tumor expression in COAD, UCEC, BRCA and READ. The KICH box plot shows higher REM2 RNA expression in normal versus tumor tissue (log2 FC = −0.715, t-test p < 0.001).
This table shows molecular features associated with REM2 in patient tissues and cancer cell lines. In patient samples, REM2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, REM2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and SOFT_TISSUE.
